There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT05074290
Recruiting
Patients with breast cancer are commonly treated with taxane chemotherapy. Some very common side effects of taxanes, such as anemia and peripheral neuropathy, are often as not well addressed during treatment, resulting in dose reductions, dose delays and early discontinuation (collectively called relative dose intensity) of these chemotherapy agents in 15-80 % of patients on these drugs. This reduction in relative dose intensity (RDI) results in worse clinical outcomes such as progression free a... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/09/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Breast Cancer
Register for Updates
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT03729115
Recruiting
This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
09/06/2024
Locations: University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT06220214
Recruiting
The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant chemotherapy on pathologic complete response rates. The device used to obtain CEDM+CEDBT images is called Siemens MAMMOMAT. This device produces two-dimensional (2D) images, as in a normal mammogram,... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Stony Brook Breast Center, Stony Brook, New York
Conditions: Breast Cancer, Locally Advanced Breast Cancer, Neoadjuvant Chemotherapy, HER2-positive Breast Cancer, Triple Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
Register for Updates
Nonlinear Elasticity Mapping of Breast Masses
NCT04863443
Recruiting
This proposed technique, called "Nonlinear Elasticity Mapping (NEM)", is an innovative approach to estimate (i.e., linear and nonlinear) elasticity to provide complementary and relevant information for identification and characterization of breast masses. The proposed technique includes imaging the (nonlinear) elasticity parameter in a quantitative manner and measuring two new and relevant parameters. These parameters, together with linear elasticity, are used to differentiate breast masses. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Breast Cancer
Register for Updates
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT06488378
Recruiting
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a type of antibody) * Olaparib (a type of PARP inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Register for Updates
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017
Recruiting
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: University of Southern California, Los Angeles, California +7 locations
Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Register for Updates
TRUDI: TDXD+Durva in HER2+/low IBC
NCT05795101
Recruiting
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Register for Updates
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT03694756
Recruiting
The aim of this study is to assess feasibility of a new imaging technology in the management of breast cancer (TMEM-MRI)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Breast Cancer
Register for Updates
Evaluation of Improved Onboard Patient Imaging
NCT06187103
Recruiting
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any chang... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
Register for Updates
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT06471673
Recruiting
This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If onc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast
Register for Updates
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT00899301
Recruiting
RATIONALE: Collecting and storing samples of tissue, blood, and urine from patients with or without breast cancer to study in the laboratory may help the study of cancer. PURPOSE: This research study is collecting and storing tissue samples from women with or without breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Breast Cancer
Register for Updates
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT05645380
Recruiting
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/23/2024
Locations: The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas +6 locations
Conditions: Triple Negative Breast Cancer, Breast Cancer
Register for Updates